TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25912221

Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 1098

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 1098

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 1098
Study: 23692696

Group type: EXPERIMENTAL
Intervention: Vaccination with phase I Coxiella burnetii vaccine (Coxevac-Ceva Sante Animale) during advanced pregnancy
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Vaccination with phase I Coxiella burnetii vaccine
Number of subjects: 719

Group type: COMPARATOR
Intervention: Control group (non-vaccinated)
Number of subjects: 719
Study: 21285447

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 20161310

Group type: EXPERIMENTAL
Intervention: Open-label rTMS (15 sessions over 3 weeks)
Number of subjects: 20
Study: 17524937

Group type: EXPERIMENTAL
Intervention: CsA (5 mg/kg/d) plus MMF (30 mg/kg/d) and prednisolone (1 mg/kg/d)
Number of subjects: 90

Group type: COMPARATOR
Intervention: CsA (8 mg/kg/d) plus MMF (30 mg/kg/d) and prednisolone (1 mg/kg/d)
Number of subjects: 90
Study: 14741172

Group type: EXPERIMENTAL
Intervention: Vaccine consisting of recombinant baculovirus-derived KSA formulated with monophosphoryl lipid A (MPL) in liposomes and emulsified in mineral oil
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Vaccine with co-administration of human recombinant GM-CSF (rGM-CSF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Vaccine without GM-CSF
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 11
Study: 12568014

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin/pyronaridine combination
Number of subjects: 32

Group type: COMPARATOR
Intervention: Dihydroartemisinin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Pyronaridine
Number of subjects: 32
Study: 9825744

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg weekly i.m. injections for 1 year
Number of subjects: 174

Group type: COMPARATOR
Intervention: Gold sodium thiomalate (GSTM) 50 mg weekly i.m. injections for 1 year
Number of subjects: 174
Study: 7854994

Group type: EXPERIMENTAL
Intervention: Loratadine (10 mg daily for 28 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (given for 14 days)
Number of subjects: 31
Study: 2805601

Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Burned children
Number of subjects: 54
Study: 809805

Group type: EXPERIMENTAL
Intervention: Low-dose EHDP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose EHDP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30252783

Group type: EXPERIMENTAL
Intervention: Regular engagement in physical activity prior to hospitalization
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Radial entry site for percutaneous coronary intervention
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Sex-related and gender-related factors
Number of subjects: 242
Study: 29045535

Group type: EXPERIMENTAL
Intervention: selumetinib 75 mg b.i.d. plus docetaxel 60 mg/m2 (SEL+DOC 60)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: selumetinib 75 mg b.i.d. plus docetaxel 75 mg/m2 (SEL+DOC 75)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo plus docetaxel 75 mg/m2 (PBO+DOC 75)
Number of subjects: 212
Study: 26001028

Group type: EXPERIMENTAL
Intervention: Awake Regional Anesthesia (RA)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Combined Spinal Caudal Anesthetic
Number of subjects: 722

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Brief Sedation
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Bloody Tap on First Attempt at Lumbar Puncture
Number of subjects: 722
Study: 23590906

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (STN DBS) switched on
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (STN DBS) switched off
Number of subjects: 12

Group type: COMPARATOR
Intervention: Visual feedback provided during the task
Number of subjects: 12
Study: 20941455

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg once daily
Number of subjects: 7337

Group type: COMPARATOR
Intervention: Enoxaparin (40 mg once‐daily or 30 mg twice‐daily)
Number of subjects: 7337
Study: 18675965

Group type: EXPERIMENTAL
Intervention: Vitrification RT/warming RT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitrification RT/warming 37 degrees C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitrification 37 degrees C/warming 37 degrees C
Number of subjects: 0

Group type: COMPARATOR
Intervention: Slow freezing RT/thawing RT
Number of subjects: 0
Study: 17296165

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Habituation Based Exposure Therapy (HBET)
Number of subjects: 16
Study: 15145916

Group type: EXPERIMENTAL
Intervention: Aerobic exercise in adolescence
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic exercise throughout lifetime
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Genetic factors
Number of subjects: 175
Study: 11387182

Group type: EXPERIMENTAL
Intervention: Nurse recall group
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: GP recall group
Number of subjects: 1906

Group type: COMPARATOR
Intervention: Audit group
Number of subjects: 1906

Group type: COMPARATOR
Intervention: Nurse recall group vs Audit group
Number of subjects: 1906

Group type: COMPARATOR
Intervention: GP recall group vs Audit group
Number of subjects: 1906

Group type: EXPERIMENTAL
Intervention: Nurse recall group vs GP recall group
Number of subjects: 1906
Study: 9591860

Group type: EXPERIMENTAL
Intervention: Listerine antiseptic
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Peridex oral rinse
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 30
Study: 7820960

Group type: COMPARATOR
Intervention: CDP-choline (cytidine diphosphate choline) administered daily for one week after a single intravenous injection.
Number of subjects: 10
Study: 2971550

Group type: EXPERIMENTAL
Intervention: Cetirizine 2 HCl
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 36
Study: 31470769

Group type: EXPERIMENTAL
Intervention: Interpersonal Strategies (yes)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intrapersonal Strategies (yes)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Interpersonal Strategies (no)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Intrapersonal Strategies (no)
Number of subjects: 102
Study: 29459064

Group type: EXPERIMENTAL
Intervention: PRP‐CRM197
Number of subjects: 0

Group type: COMPARATOR
Intervention: PRP‐T
Number of subjects: 0
Study: 27638357

Group type: COMPARATOR
Intervention: trivalent attenuated OPV (tOPV) at 6, 10, and 14 weeks
Number of subjects: 210

Group type: COMPARATOR
Intervention: bivalent OPV (bOPV) at 6, 10, and 14 weeks
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: bOPV at 6, 10, and 14 weeks plus IPV at 14 weeks
Number of subjects: 210
Study: 24499168

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg + metformin
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo + metformin
Number of subjects: 180
Study: 22310314

Group type: EXPERIMENTAL
Intervention: Longer and stronger hyperpolarizing currents
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mathematical model of human sensory axons
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Modulation of voltage dependence of I(h)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Modeling of I(h) isoforms
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Modeling of sensory axons
Number of subjects: 10
Study: 21211455

Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy plus sapheno-femoral junction (SFJ) ligation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard stripping surgery
Number of subjects: 60
Study: 18496564

Group type: EXPERIMENTAL
Intervention: Efalizumab (subcutaneous treatment for 12 weeks)
Number of subjects: 12
Study: 15902172

Group type: EXPERIMENTAL
Intervention: Solvent dehydrated cadaveric fascia lata patch
Number of subjects: 162

Group type: COMPARATOR
Intervention: No patch (control group)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Concomitant transvaginal Cooper's ligament sling procedures
Number of subjects: 162
Study: 12735677

Group type: EXPERIMENTAL
Intervention: 200 microg fenoterol
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 200 microg oxitropium bromide
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 10710765

Group type: EXPERIMENTAL
Intervention: 40 acquisition trials
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 75 acquisition trials
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 100 acquisition trials
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 125 acquisition trials
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 150 acquisition trials
Number of subjects: 50
Study: 7729740

Group type: EXPERIMENTAL
Intervention: Jackson‐Pratt closed‐suction drainage (Group 1, patients 1‐60)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No drainage (Group 2, patients 61‐120)
Number of subjects: 120
Study: 1823383

Group type: EXPERIMENTAL
Intervention: Piroxicam 5-, 10-, and 20-mg treatment groups
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 7192338

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Heparin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 16
Study: 31765343

Group type: EXPERIMENTAL
Intervention: Combined resistance training (traditional strength training + plyometrics)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Combined resistance training with weightlifting
Number of subjects: 59
Study: 27993496

Group type: COMPARATOR
Intervention: Standard cementless femoral stem
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Shorter cementless femoral stem (35-mm shorter)
Number of subjects: 60
Study: 27639753

Group type: EXPERIMENTAL
Intervention: Alirocumab 300 mg Q4W
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23490032

Group type: EXPERIMENTAL
Intervention: rtPA (tissue plasminogen activator)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24223344

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ketamine 0.5mg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) ketamine 0.5 mg/kg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 20697700

Group type: EXPERIMENTAL
Intervention: Ritonavir 300 mg b.i.d. for 4 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir 400/100 mg b.i.d. for 4 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18441036

Group type: EXPERIMENTAL
Intervention: Robot-mediated therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sling suspension phase
Number of subjects: 20
Study: 16159624

Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 12673669

Group type: EXPERIMENTAL
Intervention: Testim (1% testosterone topical gel, 50 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: AndroGel (1% testosterone topical gel, 50 mg)
Number of subjects: 29
Study: 10554519

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 8907096

Group type: EXPERIMENTAL
Intervention: Therapeutic relationship quality reported by patients early in treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Therapeutic relationship quality
Number of subjects: 0

Group type: COMPARATOR
Intervention: Therapeutic treatments (3 brief treatments for depression)
Number of subjects: 0
Study: 8443666

Group type: EXPERIMENTAL
Intervention: Scalpel (group 1)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Electrocautery (group 2)
Number of subjects: 101
Study: 3080050

Group type: EXPERIMENTAL
Intervention: High dose dexamethasone (480 mg over 12 days)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 31668575

Group type: EXPERIMENTAL
Intervention: Locking Block Modified Krackow (LBMK) technique
Number of subjects: 20

Group type: COMPARATOR
Intervention: Giftbox technique
Number of subjects: 20
Study: 30002304

Group type: EXPERIMENTAL
Intervention: MICE (20 min, 70% of maximal heart rate)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HIIE (10 × 1 min at 90% of maximal heart rate with 1 min recovery)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: HIIE
Number of subjects: 12

Group type: COMPARATOR
Intervention: CON (no exercise)
Number of subjects: 12
Study: 27682852

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) 0.25 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intravitreal bevacizumab (IVB) 0.625 mg
Number of subjects: 45
Study: 25027493

Group type: EXPERIMENTAL
Intervention: Verum auricular acupuncture plus standard obstetric care (VAAc)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Non-specific auricular acupuncture plus standard obstetric care (NSAAc)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Non-specific placebo auricular acupuncture plus standard obstetric care (PAAc)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Standard obstetric care (SOC)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: All groups (VAAc, NSAAc, PAAc)
Number of subjects: 212
Study: 25156847

Group type: COMPARATOR
Intervention: General Practitioners (GPs)
Number of subjects: 5563

Group type: EXPERIMENTAL
Intervention: Cardiologists
Number of subjects: 5563

Group type: EXPERIMENTAL
Intervention: Both GPs and Cardiologists
Number of subjects: 5563
Study: 21787210

Group type: EXPERIMENTAL
Intervention: 1% pimecrolimus cream
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0.05% clobetasol propionate cream
Number of subjects: 100

Group type: COMPARATOR
Intervention: Petrolatum (placebo)
Number of subjects: 100
Study: 19541679

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 microg kg(‐1) in normal saline 1 ml
Number of subjects: 60
Study: 17478142

Group type: EXPERIMENTAL
Intervention: Nicorandil 12 mg intravenously before PCI
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo intravenously before PCI
Number of subjects: 368
Study: 15926604

Group type: EXPERIMENTAL
Intervention: COX-2 selective inhibitors
Number of subjects: 0
Study: 12169832

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG supplementation (6 x 10(9) cfu once a day until discharge)
Number of subjects: 585
Study: 9501784

Group type: EXPERIMENTAL
Intervention: Early pushing (commencement of pushing within one hour of the diagnosis of full dilatation)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Delayed pushing (delaying pushing for a maximum of three hours from the time of diagnosis of full dilatation)
Number of subjects: 135
Study: 8700659

Group type: EXPERIMENTAL
Intervention: 6-week stress management training program
Number of subjects: 45

Group type: COMPARATOR
Intervention: Standard outpatient care
Number of subjects: 45
Study: 1909541

Group type: EXPERIMENTAL
Intervention: Pravastatin (20‐40 mg day‐1)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6357035

Group type: COMPARATOR
Intervention: Outpatient treatment
Number of subjects: 72

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both inpatient and outpatient treatment
Number of subjects: 72
Study: 30924894

Group type: EXPERIMENTAL
Intervention: Noninvasive prenatal testing (NIPT) with almost certain but limited information
Number of subjects: 2436

Group type: COMPARATOR
Intervention: Invasive testing (IT) with complete karyotyping
Number of subjects: 2436

Group type: EXPERIMENTAL
Intervention: Attitudes driven by risk aversion
Number of subjects: 2436

Group type: EXPERIMENTAL
Intervention: Attitudes driven by ambiguity aversion
Number of subjects: 2436

Group type: EXPERIMENTAL
Intervention: Attitudes involving both risk and ambiguity aversion
Number of subjects: 2436
Study: 29208884

Group type: EXPERIMENTAL
Intervention: Clonidine (100μgm) orally 60 minutes before induction of anaesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: No premedication (Group A)
Number of subjects: 60
Study: 27444313

Group type: EXPERIMENTAL
Intervention: Single-dose lafutidine 10 mg under fasting conditions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple-dose lafutidine 10 mg twice daily over 6 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single-dose lafutidine 10 mg under fed conditions
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lafutidine 10-40 mg
Number of subjects: 12
Study: 25111186

Group type: EXPERIMENTAL
Intervention: Moderate dose of alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 22055006

Group type: EXPERIMENTAL
Intervention: Single-injection PVB (20 mL 0.5% bupivacaine with 1:200,000 epinephrine at T6, n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Multiple-injection PVB (5 injections of 4 mL each at T4 to T8, n = 25)
Number of subjects: 50
Study: 19601490

Group type: EXPERIMENTAL
Intervention: Test gum 1 (TG1) containing sucrose
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Test gum 2 (TG2) containing xylitol and zinc citrate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cysteine 6 mM rinse followed by chewing test gums
Number of subjects: 14
Study: 17894652

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily
Number of subjects: 440

Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 440
Study: 15091194

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol supplementation (1000 mg/day for 3 months)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 12243810

Group type: COMPARATOR
Intervention: q.d. RT (60 Gy in 30 daily fractions) with etoposide and cisplatin (EP)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: b.i.d. RT (30 Gy in 20 fractions b.i.d. followed by a 2-week break and then 30 Gy in 20 fractions b.i.d.) with etoposide and cisplatin (EP)
Number of subjects: 234
Study: 9828758

Group type: EXPERIMENTAL
Intervention: 0.75 g fructose/kg body weight
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.75 g starch/kg body weight
Number of subjects: 12
Study: 7926574

Group type: EXPERIMENTAL
Intervention: Intracervical gel containing 0.5 mg PgE2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravaginal tablet containing 3 mg PgE2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of both gel and tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intracervical gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-sympathicomimetics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandin induction
Number of subjects: 0
Study: 1987242

Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography
Number of subjects: 79

Group type: COMPARATOR
Intervention: Transthoracic echocardiography
Number of subjects: 79
Study: 7200716

Group type: EXPERIMENTAL
Intervention: Moderate alcohol intoxication
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Alcohol consumption guised as tonic
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Alcohol expectancy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Alcohol intoxication
Number of subjects: 64
Study: 30774321

Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 300

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 300
Study: 29889843

Group type: EXPERIMENTAL
Intervention: Amoxicillin group
Number of subjects: 228

Group type: COMPARATOR
Intervention: Tetracycline group
Number of subjects: 228
Study: 27017282

Group type: EXPERIMENTAL
Intervention: G-CSF 150 µg/body/day
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: G-CSF 300 µg/body/day
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 25693332

Group type: EXPERIMENTAL
Intervention: Sugammadex 4.0 mg . kg‐1
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 98
Study: 21075537

Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of Gabapentin and Cetirizine
Number of subjects: 20
Study: 19204524

Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Illicit drug use
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Problem drug use
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Professional treatment for substance use
Number of subjects: 154
Study: 17963050

Group type: EXPERIMENTAL
Intervention: Acupuncture group (AG)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 106
Study: 15000887

Group type: EXPERIMENTAL
Intervention: Propofol (0.1 mg/kg/min) intravenously for anesthesia maintenance
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group received fentanyl 10 microg/kg intravenously and inhaled enflurane (1 %‐1.5 %)
Number of subjects: 30
Study: 12471945

Group type: EXPERIMENTAL
Intervention: Asymptotically correct method for sample size calculation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Approximate method for sample size calculation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Existing method based on crude approximation
Number of subjects: 0
Study: 9436017

Group type: EXPERIMENTAL
Intervention: Tetanus vaccination before repeat skin testing
Number of subjects: 77

Group type: COMPARATOR
Intervention: No tetanus vaccination before repeat skin testing
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Tetanus toxoid
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Mumps skin test antigen
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Candida skin test antigen
Number of subjects: 77
Study: 8083096

Group type: EXPERIMENTAL
Intervention: 0.4 Gy/hr
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: 0.8 Gy/hr
Number of subjects: 204